Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNMNASDAQ:CTORNASDAQ:IRWDNASDAQ:TORC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$3.65-7.1%$4.14$3.35▼$22.00$94.43M0.5286,668 shs68,027 shsCTORCitius Oncology$1.55+6.9%$0.94$0.55▼$4.42$110.91M-0.071.08 million shs174,660 shsIRWDIronwood Pharmaceuticals$0.70+10.1%$0.71$0.53▼$7.11$113.08M0.242.60 million shs1.73 million shsTORCresTORbio$0.67-0.5%$12.16$0.86▼$10.50$24.39M2.431.15 million shs276,567 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics-7.12%-20.13%-16.48%-48.95%-80.84%CTORCitius Oncology+6.90%+9.15%+70.33%+154.10%+154,999,900.00%IRWDIronwood Pharmaceuticals+10.12%-3.17%+14.20%-54.33%-87.74%TORCresTORbio-6.10%-18.01%-13.50%-13.53%-49.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTNMContineum Therapeutics2.7282 of 5 stars3.63.00.00.00.00.81.3CTORCitius Oncology0.9185 of 5 stars3.00.00.00.00.01.70.0IRWDIronwood Pharmaceuticals4.3664 of 5 stars4.13.00.03.41.10.81.9TORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 3.20Buy$22.50516.44% UpsideCTORCitius Oncology 2.00Hold$3.0093.55% UpsideIRWDIronwood Pharmaceuticals 2.13Hold$4.78584.51% UpsideTORCresTORbio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TORC, CTOR, IRWD, and CTNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.005/15/2025CTNMContineum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.004/16/2025IRWDIronwood PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025IRWDIronwood PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.004/15/2025IRWDIronwood PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $0.704/14/2025IRWDIronwood PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.004/14/2025IRWDIronwood PharmaceuticalsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum Therapeutics$50M1.89N/AN/A$7.66 per share0.48CTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/AIRWDIronwood Pharmaceuticals$351.41M0.32$0.05 per share14.13($1.88) per share-0.37TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics-$42.26M-$1.97N/AN/AN/AN/A-24.59%-23.49%8/12/2025 (Estimated)CTORCitius OncologyN/AN/A0.00∞N/AN/A-53.88%-18.86%N/AIRWDIronwood Pharmaceuticals$880K-$0.20N/A2.80N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)TORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/ALatest TORC, CTOR, IRWD, and CTNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A21.4721.47CTORCitius Oncology0.110.360.05IRWDIronwood PharmaceuticalsN/A3.343.34TORCresTORbioN/A20.6920.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/ACTORCitius Oncology70.52%IRWDIronwood PharmaceuticalsN/ATORCresTORbio46.19%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics11.30%CTORCitius Oncology4.57%IRWDIronwood Pharmaceuticals12.70%TORCresTORbio11.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3125.87 million22.95 millionN/ACTORCitius OncologyN/A71.55 million68.28 millionN/AIRWDIronwood Pharmaceuticals220161.82 million141.27 millionOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableTORC, CTOR, IRWD, and CTNM HeadlinesRecent News About These CompaniesJohn FlynnApril 24, 2024 | fleetowner.comAdicet Bio Inc (ACET)January 30, 2024 | investing.comTargeting the biology of aging with mTOR inhibitors - Nature.comMay 4, 2023 | news.google.comPARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLiveMarch 17, 2023 | news.google.comMichelle Chaka Joins Torc as Senior Vice President, Safety and RegulatoryFebruary 24, 2023 | finance.yahoo.comTorc names regulatory, safety SVPFebruary 24, 2023 | virginiabusiness.comGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRFebruary 8, 2023 | news.google.comPhenotypic Presentations and the Management of Moderate to ... - HealioJanuary 31, 2023 | news.google.comAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comJanuary 23, 2023 | news.google.comAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswireJanuary 23, 2023 | news.google.comTinOne Resources Inc. (TORC.V)January 10, 2023 | finance.yahoo.comresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities NewsDecember 16, 2022 | news.google.comresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities NewsDecember 12, 2022 | news.google.comBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.TechnologyNovember 3, 2022 | news.google.comTORC Investments, LLCOctober 6, 2022 | gwinnettdailypost.comCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - ForbesSeptember 19, 2022 | forbes.comFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business JournalsSeptember 12, 2022 | bizjournals.comCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRSeptember 6, 2022 | openpr.comFor preventing aging, some decades old drugs? - BioWorld OnlineJuly 18, 2022 | bioworld.comForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comJuly 8, 2022 | streetinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking StocksTORC, CTOR, IRWD, and CTNM Company DescriptionsContineum Therapeutics NASDAQ:CTNM$3.65 -0.28 (-7.12%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.76 +0.11 (+3.12%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Citius Oncology NASDAQ:CTOR$1.55 +0.10 (+6.90%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.50 -0.05 (-2.90%) As of 06/18/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Ironwood Pharmaceuticals NASDAQ:IRWD$0.70 +0.06 (+10.12%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.68 -0.02 (-2.69%) As of 06/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.resTORbio NASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
